Nucleus Drugs Private Limited - Company Profile

It is a chemicals private limited company based in Hyderabad, Telangana, India, established in 2005.
2005 Hyderabad, Telangana, India Struck Off
Last Updated:
Access Report
About Nucleus Drugs Private Limited

Nucleus Drugs Private Limited, a struck off private limited company, was established on 21 December 2005 in Hyderabad, Telangana, India. Engaging in other chemical product within the chemicals sector, it holds CIN: U24230TG2005PTC048507. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹0.10 M and a paid-up capital of ₹0.10 M.

Its leadership includes Gorla Srinivasa Reddy (Director), Dodda Sridhar Kumar (Director). Its latest AGM occurred on 26 September 2008, with the balance sheet filed on 31 March 2008. It is based at Sh No: 337, Padmavathi Plaza, Kphb Colony, Hyderabad, Telangana, 500072.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24230TG2005PTC048507

  • Registration Number

    048507

  • Incorporation Date

    21 December 2005

  • Authorized Capital

    ₹0.10 M

  • Paid-Up Capital

    ₹0.10 M

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Struck Off

Key Metrics
  • Authorised Capital ₹ 0.10 M
  • Paid Up Capital ₹ 0.10 M
  • Company Age 20 Year, 3 Months
  • Last Filing with ROC 31 Mar 2008
Company report

Nucleus Drugs Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Nucleus Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Nucleus Drugs Private Limited?
Current Directors
Name Designation Appointment Date Status
Gorla Srinivasa Reddy Director 21 Dec 2005 Current
Dodda Sridhar Kumar Director 21 Dec 2005 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Nucleus Drugs.

Enhance accessibility to Nucleus Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Nucleus Drugs revenue growth over time
Nucleus Drugs profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Nucleus Drugs?

Unlock access to Nucleus Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Nucleus Drugs?

Unlock and access historical data on people associated with Nucleus Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Nucleus Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleus Drugs's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Nucleus Drugs
Recent Activity within the Organization
  • Annual General Meeting

    The activity Nucleus Drugs Private Limited last Annual general meeting of members was held on 26 Sep 2008 as per latest MCA records. was completed.

  • Balance Sheet

    Progress on Nucleus Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2008 with Roc Hyderabad. was documented.

  • Director Appointment

    Gorla Srinivasa Reddy was appointed as a Director was appointed as a Director on 21 Dec 2005 & has been associated with this company since 20 years 3 months . was recorded as a recent event.

  • Director Appointment

    The activity Dodda Sridhar Kumar was appointed as a Director was appointed as a Director on 21 Dec 2005 & has been associated with this company since 20 years 3 months . was completed.

  • Company Incorporation

    Progress on Nucleus Drugs Private Limited was registered on 21 Dec 2005 with Roc Hyderabad & aged 20 years 3 months as per MCA records. was documented.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Nucleus Drugs Private Limited?

The CIN of Nucleus Drugs Private Limited is U24230TG2005PTC048507.

Where is Nucleus Drugs Private Limited headquartered?

Nucleus Drugs Private Limited is headquartered at Sh No: 337, Padmavathi Plaza, Kphb Colony, Hyderabad, Telangana, 500072.

When was Nucleus Drugs Private Limited incorporated?

Nucleus Drugs Private Limited was incorporated on 21 December 2005.

Who are the current directors of Nucleus Drugs Private Limited?

The current directors of Nucleus Drugs Private Limited are

What is the primary industry of Nucleus Drugs Private Limited?

The primary industry of Nucleus Drugs Private Limited is Chemicals.

Is Nucleus Drugs Private Limited a listed company?

Nucleus Drugs Private Limited is unlisted.

What is the capital structure of Nucleus Drugs Private Limited?

The authorized capital of Nucleus Drugs Private Limited is ₹0.10 M, and the paid-up capital is ₹0.10 M.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available